Study to Evaluate the Safety and Tolerability of AC-1101 Topical Gel in Patients With Granuloma Annulare

Granuloma Annulare Clinical Trial

Official title:
An Open-Label, Single Arm, Phase I Study to Evaluate the Safety and Tolerability of AC-1101 Topical Gel in Patients With Granuloma Annulare

Status Recruiting

Clinical Trial Summary

Study AC-1101-GA-001 is an early phase open-label study with a 4-week treatment and 2-week follow-up period (without treatment) to assess the safety, tolerability, and efficacy of AC-1101 gel in patients with Granuloma Annulare.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05580042
Study type	Interventional
Source	TWi Biotechnology, Inc.
Contact	Nicole Olszewski, study coordinator
Phone	203-785-5505
Email	nicole.olszewski@yale.edu
Status	Recruiting
Phase	Phase 1
Start date	October 3, 2022
Completion date	October 30, 2023

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT05650736` - Janus Kinase Inhibition in Granuloma Annulare	Phase 2
Completed	`NCT03630198` - Pain Outcomes Following Intralesional Corticosteroid Injections	Phase 4
Completed	`NCT00720980` - Granuloma Annulare Treated With Rifampin, Ofloxacin, and Minocycline Combination Therapy
Completed	`NCT05472636` - Evaluation of 41 Cases of Pediatric Granuloma Annulare
Terminated	`NCT00476697` - UVA1 Light for Scleroderma and Similar Conditions	N/A
Completed	`NCT00129428` - Ultraviolet B (UVB) Light Therapy in the Treatment of Skin Conditions With Altered Dermal Matrix	Phase 1/Phase 2
Completed	`NCT03910543` - Open-label Trial of Tofacitinib in Cutaneous Sarcoidosis and Granuloma Annulare	Phase 1